ミネラリス・セラピューティクス
Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -2.85 | $0 | -$33M |
| 2026 Q1 | -0.47 | $0 | -$39M |
| 2025 Q4 | -0.40 | $0 | -$38M |
| 2025 Q3 | -0.52 | $0 | -$29M |
| 2025 Q2 | -0.66 | $0 | -$30M |
| 2025 Q1 | -0.79 | $0 | -$45M |
| 2024 Q4 |
| -0.98 |
| $0 |
| -$67M |
| 2024 Q3 | -1.13 | $0 | -$50M |